Table 1.
Patient demographics and clinical characteristics at study visit
| Insulin glargine (n = 976) | NPH insulin (n = 506) | |
|---|---|---|
| Age, years* | 61.9 ± 11.0 | 64.3 ± 11.4 |
| Male/female, n† | 465/483 | 225/276 |
| Weight, kg‡ | 77.9 ± 12.3 | 76.8 ± 12.1 |
| BMI, kg/m2§ | 29.0 ± 4.3 | 29.0 ± 4.2 |
| HbA1c | 7.3 ± 0.9 | 7.8 ± 1.1 |
| Systolic blood pressure, mmHg¶ | 138.4 ± 15.6 | 138.6 ± 17.6 |
| Diastolic blood pressure, mmHg** | 80.0 ± 10.4 | 79.9 ± 10.3 |
| Time since diabetes diagnosis, years†† | 10.2 (0.5–49) | 12.4 (1.3–42) |
| Time since insulinisation, years‡‡ | 4 (0.25–49) | 5 (1–31) |
| Time since current insulin treatment§§ | 5.3 (3–10) months | 5 (1–31) years |
Data are presented as means ± standard deviation, percentage or median (minimum–maximum), as appropriate. Missing data (n) for insulin glargine/NPH insulin: *8/2; †28/5; ‡6/3; §8/2; ¶13/10; **14/10; ††14/6; ‡‡7/4; §§174/38. NPH, neutral protamine Hagedorn; BMI, body mass index.